Abstract :
Breast cancer is the most frequent type of cancer in Indonesia, and it also has the highest mortality rate for women worldwide. Aromatase inhibitors will be used in hormonal therapy for postmenopausal individuals with positive hormone receptors but it can cause arthralgia. This study determined the increased impact of moringa oleifera extract therapy on pain quality as measured by serum CRP levels and HAQ-DI scores in breast cancer patients taking aromatase inhibitor therapy. This research is experimental research with two groups parallel pretest and posttest control group design. 40 breast cancer patients were randomly divided into: K (control) and P1 (treatment). The P1 group was given moringa oleifera 600 mg/day for 1 month. CRP levels and HQ-Scores were measured both before and after treatment. Average age of samples is 54.88 years, with a median of 53.5 years. The difference between the pretest and posttest of CRP serum level in the control group and the treatment group (p <0,001) and between the treatment and control groups (p <0,001) showed significant results. The difference between the pretest and posttest of HAQ-DI score in the control group and the treatment group (p <0,001) and between the treatment and control groups (p <0,001) also showed significant results. Moringa oleifera extract improve quality of life of on aromatase inhibitor induced arthralgia of postmenopausal breast cancer patients with ER (+), PR (+) by reduced inflammatory status as assessed by serum CRP levels and HAQ-DI score.
